长春地区原发性高血压与G蛋白β3亚单位基因C825T多态性

目的 探讨GNB3基因C825T多态性与长春地区原发性高血压之间的关系。方法 入选原发性高血压患者269例，正常人群229例。所有研究对象常规方法提取白细胞DNA。采用多聚酶链反应结合限制性内切酶（BseDI）方法检测GNB3基因C825T多态性。结果 共成功检测268例原发性高血压患者和218例正常人。原发性高血压组与正常对照组之间基因型和等位基因频率无显著性差异（P=0．075，0．845）。各基因型之间收缩压、舒张压、脉压和平均动脉压均没有达到统计学显著性差异（P〉0．05）。结论 GNB3基因C825T多态性可能与长春地区原发性高血压无关。     

G蛋白β3亚单位基因C825T多态性与蒙古族原发性高血压的相关性研究

目的探讨G蛋白β3亚单位基因C825T多态性与蒙古族人群原发性高血压患者之间的关系。方法采用Sequenom系统检测分析方法检测124例健康人和143例高血压患者的G蛋白β3亚单位基因C825T多态性。结果（1）蒙古族人群GNB3基因C825T位点CC、CT、TT基因型频率在高血压组和正常血压组分别为0．48、0．41、0．11和0．43、0．47、0．10，差异无显著性（χ^2=0．162，P=0．688；OR：1．176，95％CI 0．533～2．592）；C、T等位基因频率在高血压组和对照组分别为0．69、0．31和0．67、0．33差异无显著性（χ^2=0．094，P=0．759；OR：0．945，95％CI0．657—1．358）。（2）蒙古族人群GNB3基因C825T位点CC、CT、TT基因型频率在单纯收缩压增高组和正常血压组分别为0．57、0．35、0．08和0，43、0．47、0．10．差异无显著性（χ^2=0．733．P=0．392；OR：1．957，95％CI0．623—6．143）；C、T等位基因频率在单纯高血压组和对照组分别为0．74、0．26和0．67、0．33，差异无显著性（χ^2=2．133，P=0．144；OR：0．697，95％CI0．428—1．133）。结论G蛋白β3亚单位基因C825T位点与蒙古族人群原发性高血压的发生可能无关，不是蒙古族人群原发性高血压的遗传标志．     

凝血酶及其受体在PTCA术后再狭窄形成中的作用

ＰＴＣＡ术后，受损伤动脉局部凝血酶产生增加，凝血酶受体表达上调，可促进局部血小板性血栓形成，促进血管平滑肌细胞的增殖，增加其他生长因子如ｂＦＧＦ、ＰＤＧＦ等的产生及其促血管平滑肌细胞增殖作用。对抑制凝血酶生成、抑制其活性或阻断其受体等措施的进一步研究，可为ＰＴＣＡ术后再狭窄的预防提供有效方法。     

牡丹江地区汉族及朝鲜族高血压人群中G蛋白β3亚单位825C/T的多态性

背景：G蛋白β3亚单位825C/T基因多态性与朝鲜族人群原发性高血压是否存在关系尚无报道。 目的：研究牡丹江地区朝鲜族、汉族高血压患者C825T基因的多态性。 方法：纳入2008-09/2010-08在牡丹江市朝鲜民族医院内科就诊的原发性高血压患者224例作为病例组,同时选取同时期的门诊体检的健康者196例作为对照。用PCR-RFLP检测G蛋白β3亚单位基因C825T多态性,观察TT,CT,CC基因型频率及等位基因频率。 结果与结论：PCR-RFLP检测结果显示牡丹江地区朝鲜族高血压患者与朝鲜族健康人TT,CT,CC基因型频率差异无显著性意义(P > 0.05);T,C等位基因频率差异有显著性意义(P < 0.05)。而牡丹江地区汉族人群中TT,CT,CC基因型分布在高血压人群和正常人群差异有显著性意义(P < 0.05),而T,C等位基因频率差异无显著性意义(P > 0.05)。朝鲜族高血压组等位基因C的比例较高,而汉族高血压组等位基因T的比例较高,存在民族异质性。提示G蛋白β3亚单位基因C825T多态性与牡丹江地区朝鲜族高血压无关联,但其是牡丹江地区汉族高血压的危险因素。     

G蛋白β3基因多态性与人类疾病

人类G蛋白 β3 亚单位基因 (GNB3)外显子 10第 82 5位点的一个多态性C→T与高血压、肥胖症、2型糖尿病以及双极情感障碍和抑郁症等均表现出极大的相关性。 82 5T等位基因携带者 (CT +TT)特别是TT纯合子患高血压及其并发症、超重或肥胖、2型糖尿病以及双极情感障碍和抑郁症等的危险性较CC纯合子显著增高。但这几种疾病 (特别是前三者 )是否由共同的病理生理机制发生还是因其中某一种占主导地位而诱发疾病目前尚不清楚。     

怀化地区侗族高血压高发人群G蛋白β3亚单位基因825C/T多态性研究

目的探讨G蛋白β3亚单位(GNB3)基因825C/T多态性与怀化侗族高血压高发人群原发性高血压之间的关系.方法采用聚合酶链反应结合限制性内切酶片段长度多态分析方法(PCR-RFLP)检测96例怀化侗族高血压病人和89例健康人的GNB3 825C/T等位基因频率和基因型频率.结果高血压组GNB3 825C/T基因型频率(CC18.8%、CT59.4%、 TT21.8%)等位基因频率(C48.4%、T51.6%)与正常对照组基因型频率(CC24.7%、CT52.8%、 TT22.5%)等位基因频率(C51.1%、T48.9%)比较无显著差异;CC基因型患者与CT TT型基因型患者比较,收缩压和舒张压无显著性差异.结论 GNB3基因多态性与怀化侗族人群原发性高血压无关.     

蒙古族肥胖人群与ADRB1G1165C、GNB3C825T基因多态性交互作用的联合分析

目的 针对内蒙古蒙古族人群的ADRB1基因G1165C位点、GNB3基因C825T位点进行多因素分析,探讨ADRB1基因G1165C位点、GNB3基因C825T位点与蒙古族人群肥胖的相关性.方法 采用Sequenom系统检测183例蒙古族健康人和90例肥胖患者的ADRB1基因G1165C位点、GNB3基因C825T位点...     

G蛋白β3亚单位基因多态性与原发性高血压的相关性研究

目的探讨G蛋β3亚单位基因(GNB3)多态性与原性高血压的关系。方法高血压患者110例,健康对照者150例,采用聚合酶链反应(PCR)和限制性内切酶切割的方法分析GNB3多态性及分布,同时记录性别及血压。结果与健康组比较,EH组各基因型分布及等位基因频率无显著性差异,CC与T等位基因比较P=0.051;EH组中TT基因型患者收缩压水平显著高于CC/CT型(P=0.003)。结论G蛋白β3亚单位基因(GNB3)多态性参与高血压的发生,发展过程,且与收缩压密切相关。     

成都地区肥胖患者GNB3基因825C/T多态性研究

目的 研究G蛋白β3亚单位(G-protein β3 subunit,GNB3)基因825C/T多态性是否与中国人肥胖有关联,为探讨肥胖的分子遗传基础提供依据.方法 应用聚合酶链反应-限制性片段长度多态性分析法,对成都地区270名非肥胖者及129例肥胖患者GNB3基因825C/T多态性位点进行分析,采用酶法和单向免疫扩散法对血脂和载脂蛋白水平进行测定.结果 GNB3基因825C/T位点C、T等位基因的频率在肥胖组为0.531、0.469,在非肥胖组为0.528、0.472,两绀间等传基因的频率差异无统计学意义(P＞0.05).中国人825C/T位点T等位基因频率(0.471,合并组)较德国白人的0.319显著增高(P＜0.01),而低于非洲黑人的0.788(P＜0.01),与日本人的0.487相近(P＞0.05).825C/T位点在非肥胖组TT基因型携带者血清甘油三酯水平高于CT基因型者(P＜0.05);在肥胖组CC基因型携带者血清高密度脂蛋白胆固醇水平较CT基因型者降低(P＜0.05).进一步按件别分层后,这种差异仪在相应各组的男性、女性亚组存在;此外,非肥胖男性TT型者、女性CC型者血清高密度脂蛋白胆固醇、载脂蛋白A Ⅰ水平分别低于和高于相应业组CT型者(P＜0.05),肥胖男性亚组TT型者血清载脂蛋白A Ⅰ水平高于CC型者(P＜0.05).结论 GNB3基因825C/T多态性与中国成都地区汉族人肥胖无关联,但与血清甘油三脂、高密度脂蛋白胆同醇和载脂蛋白A Ⅰ水平含量有关,且具有性别差异存在.     

5-羟色胺转运体、G蛋白β3亚单位基因多态性与抑郁症的相关性研究

目的:观察5-羟色胺转运体基因(5-HTTLPR)和G蛋白β3亚单位基因(GNβ3 C825T)多态性在中国抑郁症患者中的分布情况及特点,探讨抑郁症发生的遗传机制。方法:采用聚合酶链反应和限制性片段内切酶的方法检测了180例抑郁症患者(其中男性84例,女性96例)及156例健康人对照组的5-HTTLPR和GNβ3 C825T基因多态性。结果:5-HTTLPR和GNβ3 C825T基因多态性在两组人群中的分布差异均有显著性,抑郁症组的5-HTTLPR SS基因型及S等位基因频率和GNβ3 825TT基因型及T等位基因频率均高于对照组(P<0.05)。进一步联合基因型分析显示:同时具有5-HTTLPRS和GNβ3 825T等位基因者患抑郁症的相对危险度(OR=3.25,P=0.001)比单独具有5-HTTLPRS等位基因(OR=1.817,P=0.01)或GNβ3 825T等位基因者高(OR=2.214,P=0.001)。结论:5-HTTLPR和GNβ3 C825T基因可能均是抑郁症的易感基因,且显示这两个基因在抑郁症的发病中存在微效协同作用。     

血管内放射治疗的远期疗效和并发症

血管内放射治疗是防治经皮冠状动脉成形术 (Percutaneous translum inal coronary angioplasty,PTCA)和支架术后发生再狭窄的一项新技术。对其体外和临床实验中的远期疗效和并发症的正确认识 ,有利于临床综合治疗方案的制订     

冠状动脉球囊成形术及支架术后再狭窄

绝大部分冠心病患者的临床表现是由冠状动脉严重狭窄所致 ,很少一部分冠状动脉狭窄虽不严重 ,但合并痉挛仍可引起心绞痛或心肌梗塞。冠心病的治疗除了药物治疗及危险因素的控制方面近年来发展较快外 ,冠状动脉的血运重建治疗近二十年来也有了长足的进步。目前经皮冠状动脉球囊成形术(ＰＴＣＡ)已成为与药物、外科搭桥手术并驾齐驱的主要治疗手段。虽然ＰＴＣＡ治疗冠心病即刻临床效果满意 ,但术后血管再狭窄在一定程度上影响了治疗的最终效果 ,并限制了ＰＴＣＡ的发展。近十年冠状动脉内支架的应用 ,显著降低了治疗时的急性缺血并发症 ,同时…     

Microalbuminuria is no risk factor for restenosis following percutaneous transluminal coronary angioplasty

Summary Microalbuminuria is known to be associated with an increased risk for cardiovascular disease. It is detectable in acute myocardial infarction and could therefore also be a risk factor for reocclusion after percutaneous transluminal coronary angioplasty (PTCA). In our study follow-up coronary angiography was performed in 50 consecutive patients with a mean age of 56 years (38–70) on average 14 months after successful PTCA. Restenosis was defined as a decrease in diameter of 25% or more of the original result and one of at least 50% in vessel diameter. In the restenosis group there were 23 patients, and 27 showed no restenosis. The family history and anamnestic risk profile, results of the initially performed coronary angiography, and laboratory risk factors were comparable in the two groups. Median microalbumin was 11.2 mg/g creatinine in those with restenosis and 9.8 mg/g creatinine in those without. Using a cutoff of 10.0 mg/g creatinine, 12 of 23 patients with restenosis (52%) and 10 of 27 patients without (37%) were positive for microalbuminuria (NS). The incidence of microalbuminuria was higher in both groups compared to historical controls. Thus, in the restenosis group the incidence of microalbuminuria tended to be higher than in the nonrestenosis group, but since this difference did not reach statistical significance, it cannot be used to predict the risk of reocclusion after PTCA.Abbreviations PTCA percutaneous transluminal coronary angioplasty - MA microalbuminuria - R restenosis group - NR group without restensosis     

Lack of association between the G protein beta3 subunit gene and essential hypertension in Chinese: a case-control and a family-based study

A C825T polymorphism of the gene encoding the G protein ₃ subunit (GNB3) is associated with enhanced G protein activity and increased intracellular signal transduction. The 825T allele has been implicated in the development of hypertension in some ethnic groups, especially in whites. Studies in Asians and blacks are more controversial, and little information is available on this polymorphism in the susceptibility to hypertension in the Chinese population. Furthermore, the inconsistency between studies may be due to genetic heterogeneity of the population selected and/or the lack of statistical power. We investigated the relationship of this polymorphism with hypertension in two independent northern Chinese populations using both a case-control and a family-based study design. The GNB3 C825T polymorphism was determined by polymerase chain reaction and restriction enzyme digestion. In the case-control study which included 585 hypertensive case subjects and 580 normotensive control subjects there was no significant association between the polymorphism and hypertension status or blood pressure levels. The lack of association was confirmed by the results obtained in 181 hypertensive families using both transmission disequilibrium test and sib transmission disequilibrium test. No preferential transmission was observed for the GNB3 825T allele to the affected subjects. Furthermore, there was no significant association between the polymorphism and body mass index in the case-control study. Therefore our work does not provide evidence in favor of GNB3 C825T being a candidate gene for conferring genetic susceptibility to hypertension or obesity in northern Chinese population.Abbreviations TDT Transmission/disequilibrium test     

Coronary atherosclerosis and interventions: Pathological sequences and restenosis

The primary cause of cardiac morbidity and mortality in developed countries is ischemic (coronary) heart disease. The incidence of this disease is virtually all due to atherosclerosis, and ischemic heart disease is also the most prevalent disease in the industrialized world, causing over 40% of all deaths in the United States and Western Europe. In Japan, the incidence of ischemic heart disease due to coronary atherosclerosis is gradually increasing as well. Compared with the classical nomenclature of atherosclerosis; that is, fatty streak, fibrous plaque and complicated lesions, the term Stary's classification has been universally accepted because it reflects the more recently acquired knowledge about the morphological and biochemical details of the processes in coronary atherosclerosis, which have been obtained by new strategies such as angioscopy, intravascular ultrasound and molecular biological methods. The term Stary's classification has been applied for the coronary atherosclerosis of patients with acute coronary syndrome at the National Cardiovascular Center, for the analysis of predisposing atherosclerosis of these patients. The recent findings regarding acute coronary syndrome resulting from a rupture of coronary atherosclerotic plaques indicate that this syndrome is probably the most important mechanism underlying the sudden onset. It has been found that the risk of plaque rupture may depend more on plaque composition than on plaque size. Plaques rich in soft extracellular lipids and macrophages are possibly more vulnerable to plaque rupture. Two of the goals of the present review are to clarify how plaque disruption occurs and to elucidate the relationship between plaque disruption and coronary risk factors in elderly Japanese patients with acute coronary syndrome. Coronary stents have been shown to be efficacious in the treatment of acute and threatened closure complicating percutaneous transluminal coronary angioplasty (PTCA) and have produced encouraging initial results in the prevention of restenosis. In the autopsy study of restenosis after PTCA, it was observed that dense caps of collagen fibers in the adventitia in the vicinity of the disrupted internal elastic laminae were present in all of the remodeling lesions. It is suggested that remodeling, which resulted in adventitial scarring, is one of the major causative factors of restenosis after PTCA. The long-term success of stenting, however, remains limited by the occurrence of late in-stent restenosis, with an incidence of 20-42% depending on the stent design and the patient population studied. Another aim of the present review is to describe the pathological mechanism of restenosis after PTCA and/or stent replacement and, consequently, the vascular remodeling that occurs around adventitial tissue after PTCA and intimal hyperplasia that is chronically irritated by a foreign body granulomatous reaction after stenting. Finally, the results of the investigation of the effect of a tissue factor pathway inhibitor on the prevention of interventional restenosis is described.     

eNOS基因体外转染对大鼠颈总动脉球囊损伤后血管平滑肌细胞增殖规律的影响

目的将内皮型一氧化氮合酶(endothilialnitircoxidesynthase,eNOS)基因,通过基因工程技术转染至体外培养的大鼠颈总动脉球囊损伤后的血管平滑肌细胞中,观察其对血管平滑肌细胞增殖规律的影响。方法三月龄雄性Wastar大鼠20只,分为正常对照组、空白对照组、pcDNA3.1(-)转染组和pcDNA3.1-eNOS转染组,每组各5只。除正常对照组外15只Wastar大鼠,施行经皮冠状动脉腔内成形术(PTCA)。术后一月,处死所有20只大鼠,取出左侧颈总动脉,以组织块贴壁法培养损伤后血管平滑肌细胞,采用脂质体载体Fugene6介导真核表达载体pcDNA3.1-eNOS和空载体pcDNA3.1(-)分别转染eNOS转染组和pcDNA3.l(-)转染组的平滑肌细胞,以RT-PCR法、原位杂交法和免疫荧光法检测eNOS基因的表达;以MTT法检测细胞增殖程度。结果在转染pcDNA3.l-eNOS基因的损伤后血管平滑肌细胞中可以检测出eNOSmRNA和蛋白的表达,且其细胞增殖程度显著低于未转染eNOS基因者(P<0.05)。结论eNOS基因体外转染可以明显抑制大鼠颈总动脉球囊损伤后血管平滑肌细胞的增殖活性。     

Influence of metal alloy and the profile of coronary stents in patients with multivessel coronary disease

BACKGROUND:

In Brazil, despite the recommendations of the Brazilian Society of Hemodynamics and Interventional Cardiology, the National Health System has not yet approved the use of drug-eluting stents. In percutaneous coronary interventions performed in the public and part of the private health care system, bare metal stents are used as the only option. Therefore, new information on bare metal stents is of great importance. The primary endpoint was to evaluate the influence of the alloy and the profile of coronary stents on late loss and restenosis rates 6 months after implantation in patients with multivessel coronary disease.

METHODS:

Single center, randomized and prospective study comparison of cobalt–chromium versus stainless steel stent implantation in 187 patients with multivessel coronary disease. At least one cobalt–chromium and one stainless steel stent were implanted per patient.

RESULTS:

Mean age of patients was 59.5±10.1 years with a prevalence of males (66.3%) and patients with acute coronary syndrome (56%). Baseline clinical characteristics were similar with hypertension in 146 (78%), dyslipidemia in 85 (45.5%) and diabetes in 68 (36.4%). Two hundred and twenty-nine cobalt–chromium and 284 stainless steel stents were implanted. Angiographic variables showed no statistically significant difference. Angiographic follow-up to 6 months after implantation showed similar late loss and restenosis rates.

CONCLUSION:

The use of two different alloys, stainless steel and cobalt–chrome stents, in the same patient and in the same vessel produced similar 6-month restenosis and late loss rates.     

Effects of Low Dose Pioglitazone on Restenosis and Coronary Atherosclerosis in Diabetic Patients Undergoing Drug Eluting Stent Implantation

Purpose

Thiazolidinediones are insulin-sensitizing agents that reduce neointimal proliferation and the adverse clinical outcomes associated with percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM). There is little data on whether or not low dose pioglitazone reduces adverse clinical outcomes.

Materials and Methods

The study population included 121 DM patients with coronary artery disease and they were randomly assigned to 60 patients taking 15 mg of pioglitazone daily in addition to their diabetic medications and 61 patients with placebo after the index procedure with drug-eluting stents (DESs). The primary end points were rate of in-stent restenosis (ISR) and change in atheroma volume and in-stent neointimal volume. The secondary end points were all-cause death, myocardial infarction (MI), stent thrombosis and re-PCI.

Results

There were no statistical differences in the clinical outcomes and the rate of ISR between the two groups [all-cause death; n=0 (0%) in the pioglitazone group vs. n=1 (1.6%) in the control group, p=0.504, MI; n=2 (3.3%) vs. n=1 (1.6%), p=0.465, re-PCI; n=6 (10.0%) vs. n=6 (9.8%), p=0.652, ISR; n=4 (9.3%) vs. n=4 (7.5%), p=1.000, respectively]. There were no differences in changes in neointimal volume, percent neointimal volume, total plaque volume and percent plaque volume between the two groups on intravascular ultrasonography (IVUS) study.

Conclusion

Our study demonstrated that low dose pioglitazone does not reduce rate of ISR, neointimal volume nor atheroma volume in DM patients who have undergone PCI with DESs, despite the limitations of the study.     

Relationship between free-radical lipid oxidation and efficiency of coronary angioplasty in coronary patients

Low-dose (250 mg daily) oral probucol produces a significant antioxidant effect in coronary patients: increases activity of glutathione peroxidase (enzyme utilizing lipoperoxides) and reduces the content of free-radical oxidation products in the blood. Probucol therapy for 7 days before and for 6 months after coronary angioplasty significantly reduces the severity of coronary artery stenosis. __________ Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 144, No. 11, pp. 503–506, November, 2007